Lysoway Therapeutics
Developing small-molecule modulators of lysosomal ion channels for neurodegenerative diseases.
About
Lysoway Therapeutics is a biopharmaceutical company focused on developing novel small-molecule therapies that modulate lysosomal ion channels. Their primary focus is on addressing neurodegenerative diseases, with a specific program targeting TMEM175 agonists for Parkinson's disease, supported by grants from The Michael J. Fox Foundation for Parkinson's Research. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does Lysoway Therapeutics do?
Lysoway Therapeutics is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Healthcare, Neuroscience. It is based in Cambridge, Massachusetts, USA and was founded in 2021. Public records show $45M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Lysoway Therapeutics raised?
Lysoway Therapeutics has raised a total of $45M in funding. The most recent round on record is Series A.
Where is Lysoway Therapeutics headquartered?
Lysoway Therapeutics is headquartered in Cambridge, Massachusetts, USA.
When was Lysoway Therapeutics founded?
Lysoway Therapeutics was founded in 2021.
What industry does Lysoway Therapeutics operate in?
Lysoway Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Neuroscience, Biotech.
What is Lysoway Therapeutics's current status?
Lysoway Therapeutics's current operating status is: Inactive.